Polymeric oncolytic adenovirus for cancer gene therapy

Citations

WEB OF SCIENCE

62
Citations

SCOPUS

67

초록

Oncolytic adenovirus (Ad) vectors present a promising modality to treat cancer. Many clinical trials have been done with either naked oncolytic Ad or combination with chemotherapies. However, the systemic injection of oncolytic Ad in clinical applications is restricted due to significant liver toxicity and immunogenicity. To overcome these issues, Ad has been engineered physically or chemically with numerous polymers for shielding the Ad surface, accomplishing extended blood circulation time and reduced immunogenicity as well as hepatotoxicity. In this review, we describe and classify the characteristics of polymer modified oncolytic Ad following each strategy for cancer treatment. Furthermore, this review concludes with the highlights of various polymer-coated Ads and their prospects, and directions for future research. (C) 2015 Elsevier B.V. All rights reserved.

키워드

Oncolytic adenovirusClinical trialsCancer gene therapyOncolytic Ad/polymer hybrid vectorActive targetingTumor microenvironment targetingSystemic administrationMETASTATIC PROSTATE-CANCERDOUBLE-SUICIDE GENEIMPROVED SYSTEMIC DELIVERYHUMORAL IMMUNE-RESPONSESI/II CLINICAL-TRIALPHASE-I TRIALBIOREDUCIBLE POLYMERTUMOR-GROWTHREPLICATION-COMPETENTRADIATION-THERAPY
제목
Polymeric oncolytic adenovirus for cancer gene therapy
저자
Choi, Joung-WooLee, Young SookYun, Chae-OkKim, Sung Wan
DOI
10.1016/j.jconrel.2015.10.009
발행일
2015-12
유형
Article
저널명
Journal of Controlled Release
219
페이지
181 ~ 191